NASDAQ:ATRS - Antares Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Antares Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.72 -0.17 (-3.48 %) (As of 12/10/2019 02:49 AM ET) Add Compare Today's Range$4.53Now: $4.72▼$4.8650-Day Range$3.28MA: $4.14▼$5.0552-Week Range$2.53Now: $4.72▼$5.13Volume2.88 million shsAverage Volume1.18 million shsMarket Capitalization$770.43 millionP/E RatioN/ADividend YieldN/ABeta0.91 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:ATRS Previous Symbol CUSIP03664210 CIK1016169 Webhttp://www.antarespharma.com/ Phone609-359-3020Debt Debt-to-Equity Ratio1.00 Current Ratio2.95 Quick Ratio2.46Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$63.55 million Price / Sales12.12 Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book18.88Profitability EPS (Most Recent Fiscal Year)($0.04) Net Income$-6,510,000.00 Net Margins-0.56% Return on Equity-1.40% Return on Assets-0.56%Miscellaneous Employees165 Outstanding Shares163,226,000Market Cap$770.43 million Next Earnings Date2/27/2020 (Estimated) OptionableOptionable Receive ATRS News and Ratings via Email Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ATRS Rates by TradingView Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions What is Antares Pharma's stock symbol? Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS." How were Antares Pharma's earnings last quarter? Antares Pharma Inc (NASDAQ:ATRS) released its earnings results on Tuesday, November, 5th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.02) by $0.03. The specialty pharmaceutical company had revenue of $34.31 million for the quarter, compared to analyst estimates of $26.36 million. Antares Pharma had a negative return on equity of 1.40% and a negative net margin of 0.56%. View Antares Pharma's Earnings History. When is Antares Pharma's next earnings date? Antares Pharma is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Antares Pharma. What price target have analysts set for ATRS? 3 brokerages have issued twelve-month price targets for Antares Pharma's stock. Their forecasts range from $1.99 to $5.65. On average, they expect Antares Pharma's stock price to reach $4.05 in the next twelve months. This suggests that the stock has a possible downside of 14.3%. View Analyst Price Targets for Antares Pharma. What is the consensus analysts' recommendation for Antares Pharma? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Antares Pharma. Has Antares Pharma been receiving favorable news coverage? Media coverage about ATRS stock has been trending somewhat positive recently, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Antares Pharma earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Antares Pharma. Are investors shorting Antares Pharma? Antares Pharma saw a decline in short interest during the month of November. As of November 15th, there was short interest totalling 4,040,000 shares, a decline of 10.0% from the October 31st total of 4,490,000 shares. Based on an average daily trading volume, of 994,700 shares, the days-to-cover ratio is currently 4.1 days. Currently, 2.7% of the shares of the company are sold short. View Antares Pharma's Current Options Chain. Who are some of Antares Pharma's key competitors? Some companies that are related to Antares Pharma include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Atrion (ATRI), Anika Therapeutics (ANIK), Cerus (CERS), OraSure Technologies (OSUR) and Utah Medical Products (UTMD). What other stocks do shareholders of Antares Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Conatus Pharmaceuticals (CNAT), Hi-Crush Partners (HCLP), NVIDIA (NVDA), Prospect Capital (PSEC), Novavax (NVAX), Macquarie Infrastructure (MIC), Enviva Partners (EVA), Innovus Pharmaceuticals (INNV) and Advanced Micro Devices (AMD). Who are Antares Pharma's key executives? Antares Pharma's management team includes the folowing people: Mr. Robert F. Apple, CEO, Pres & Director (Age 53)Mr. Fred M. Powell, Exec. VP & CFO (Age 58)Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 52)Dr. James Patrick Tursi, EVP, Head of R&D & Chief Medical Officer (Age 54)Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 56) Who are Antares Pharma's major shareholders? Antares Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (2.44%), Sargent Investment Group LLC (2.04%), State of New Jersey Common Pension Fund D (0.47%), Perkins Capital Management Inc. (0.19%), California Public Employees Retirement System (0.16%) and California State Teachers Retirement System (0.15%). Company insiders that own Antares Pharma stock include Jacques Gonella, Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma. Which major investors are selling Antares Pharma stock? ATRS stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Virtu Financial LLC, Perkins Capital Management Inc., Barclays PLC, SG Americas Securities LLC and Metropolitan Life Insurance Co NY. Company insiders that have sold Antares Pharma company stock in the last year include Jacques Gonella, Leonard S Jacob and Thomas J Garrity. View Insider Buying and Selling for Antares Pharma. Which major investors are buying Antares Pharma stock? ATRS stock was bought by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Sargent Investment Group LLC, Monarch Partners Asset Management LLC, California Public Employees Retirement System, Russell Investments Group Ltd., Squarepoint Ops LLC, Cadence Capital Management LLC and CWM LLC. View Insider Buying and Selling for Antares Pharma. How do I buy shares of Antares Pharma? Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Antares Pharma's stock price today? One share of ATRS stock can currently be purchased for approximately $4.72. How big of a company is Antares Pharma? Antares Pharma has a market capitalization of $770.43 million and generates $63.55 million in revenue each year. The specialty pharmaceutical company earns $-6,510,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. Antares Pharma employs 165 workers across the globe.View Additional Information About Antares Pharma. What is Antares Pharma's official website? The official website for Antares Pharma is http://www.antarespharma.com/. How can I contact Antares Pharma? Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected] MarketBeat Community Rating for Antares Pharma (NASDAQ ATRS)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 345 (Vote Outperform)Underperform Votes: 268 (Vote Underperform)Total Votes: 613MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe ATRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/10/2019 by MarketBeat.com StaffFeatured Article: How to Use a Moving Average for Trading